New drug combo aims to tame AML in patients too frail for strong chemo
NCT ID NCT03513484
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 1 trial tests the combination of nintedanib and azacitidine in older adults with acute myeloid leukemia (AML) who are not candidates for intensive chemotherapy. The goal is to find the safest dose of nintedanib when given with azacitidine and to see how well patients tolerate the combination. Up to 44 participants will receive treatment for up to 6 cycles, with the option to continue if it helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
nintedanib and azacitidine
What this could lead to
If it works, this could lead to a new treatment option for older AML patients who cannot tolerate intensive chemotherapy.
What could go wrong
This is an early phase 1 trial with only 44 participants, focused on safety and dosing. The combination may not be effective or could cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Northwestern University
Chicago, Illinois, 60611, United States